Endoscopic treatment of vesicoureteral reflux in children with posterior urethral valves

Tayfun Oktar, Omer Acar, Ahmet Sancaktutar, Oner Sanli, Tzevat Tefik, Orhan Ziylan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: We reviewed the clinical outcome of endoscopic injection therapy in children with vesicoureteral reflux persisting after posterior urethral valve ablation. Methods: We retrospectively reviewed the charts of 16 patients with posterior urethral valves who have undergone endoscopic injection to correct persistent reflux after successful relief of urethral obstruction. Breakthrough urinary tract infections, persistent highgrade reflux and failed ureteroneocystostomy were the indications of endoscopic antireflux surgery. Results: Reflux was grade I in 1, grade II in 3, grade III in 11 and grade IV in 4 ureters. Mean age at injection was 6.9 ± 3.8 years and the mean interval from initial intervention to injection was 4.3 ± 2.4 years. Injected material was dextranomer/hyaluronic acid in the majority (87.5 %) of cases. Reflux was resolved or downgraded in 12 ureters (63.1 %) after a single injection. All failed cases had urodynamically documented bladder dysfunction. Conclusion: More than half of the patients with vesicoureteral reflux, persisting after initial valve ablation, showed complete resolution or significant downgrading in their reflux grade after endoscopic injection. Given the technical difficulties and potential complications of open surgical reimplantation in valve patients, endoscopic subureteral injection can be considered as an effective alternative to cure persistent vesicoureteral reflux.

Original languageEnglish (US)
Pages (from-to)1305-1309
Number of pages5
JournalInternational Urology and Nephrology
Volume44
Issue number5
DOIs
StatePublished - Oct 1 2012

Fingerprint

Vesico-Ureteral Reflux
Injections
Ureter
Therapeutics
Urethral Obstruction
Replantation
Hyaluronic Acid
Urinary Tract Infections
Urinary Bladder

Keywords

  • Endoscopic injection
  • Posterior urethral valve
  • Vesicoureteral reflux

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Endoscopic treatment of vesicoureteral reflux in children with posterior urethral valves. / Oktar, Tayfun; Acar, Omer; Sancaktutar, Ahmet; Sanli, Oner; Tefik, Tzevat; Ziylan, Orhan.

In: International Urology and Nephrology, Vol. 44, No. 5, 01.10.2012, p. 1305-1309.

Research output: Contribution to journalArticle

Oktar, Tayfun ; Acar, Omer ; Sancaktutar, Ahmet ; Sanli, Oner ; Tefik, Tzevat ; Ziylan, Orhan. / Endoscopic treatment of vesicoureteral reflux in children with posterior urethral valves. In: International Urology and Nephrology. 2012 ; Vol. 44, No. 5. pp. 1305-1309.
@article{88bed360e1b04692a105c504b82fe025,
title = "Endoscopic treatment of vesicoureteral reflux in children with posterior urethral valves",
abstract = "Purpose: We reviewed the clinical outcome of endoscopic injection therapy in children with vesicoureteral reflux persisting after posterior urethral valve ablation. Methods: We retrospectively reviewed the charts of 16 patients with posterior urethral valves who have undergone endoscopic injection to correct persistent reflux after successful relief of urethral obstruction. Breakthrough urinary tract infections, persistent highgrade reflux and failed ureteroneocystostomy were the indications of endoscopic antireflux surgery. Results: Reflux was grade I in 1, grade II in 3, grade III in 11 and grade IV in 4 ureters. Mean age at injection was 6.9 ± 3.8 years and the mean interval from initial intervention to injection was 4.3 ± 2.4 years. Injected material was dextranomer/hyaluronic acid in the majority (87.5 {\%}) of cases. Reflux was resolved or downgraded in 12 ureters (63.1 {\%}) after a single injection. All failed cases had urodynamically documented bladder dysfunction. Conclusion: More than half of the patients with vesicoureteral reflux, persisting after initial valve ablation, showed complete resolution or significant downgrading in their reflux grade after endoscopic injection. Given the technical difficulties and potential complications of open surgical reimplantation in valve patients, endoscopic subureteral injection can be considered as an effective alternative to cure persistent vesicoureteral reflux.",
keywords = "Endoscopic injection, Posterior urethral valve, Vesicoureteral reflux",
author = "Tayfun Oktar and Omer Acar and Ahmet Sancaktutar and Oner Sanli and Tzevat Tefik and Orhan Ziylan",
year = "2012",
month = "10",
day = "1",
doi = "10.1007/s11255-012-0240-y",
language = "English (US)",
volume = "44",
pages = "1305--1309",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Endoscopic treatment of vesicoureteral reflux in children with posterior urethral valves

AU - Oktar, Tayfun

AU - Acar, Omer

AU - Sancaktutar, Ahmet

AU - Sanli, Oner

AU - Tefik, Tzevat

AU - Ziylan, Orhan

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose: We reviewed the clinical outcome of endoscopic injection therapy in children with vesicoureteral reflux persisting after posterior urethral valve ablation. Methods: We retrospectively reviewed the charts of 16 patients with posterior urethral valves who have undergone endoscopic injection to correct persistent reflux after successful relief of urethral obstruction. Breakthrough urinary tract infections, persistent highgrade reflux and failed ureteroneocystostomy were the indications of endoscopic antireflux surgery. Results: Reflux was grade I in 1, grade II in 3, grade III in 11 and grade IV in 4 ureters. Mean age at injection was 6.9 ± 3.8 years and the mean interval from initial intervention to injection was 4.3 ± 2.4 years. Injected material was dextranomer/hyaluronic acid in the majority (87.5 %) of cases. Reflux was resolved or downgraded in 12 ureters (63.1 %) after a single injection. All failed cases had urodynamically documented bladder dysfunction. Conclusion: More than half of the patients with vesicoureteral reflux, persisting after initial valve ablation, showed complete resolution or significant downgrading in their reflux grade after endoscopic injection. Given the technical difficulties and potential complications of open surgical reimplantation in valve patients, endoscopic subureteral injection can be considered as an effective alternative to cure persistent vesicoureteral reflux.

AB - Purpose: We reviewed the clinical outcome of endoscopic injection therapy in children with vesicoureteral reflux persisting after posterior urethral valve ablation. Methods: We retrospectively reviewed the charts of 16 patients with posterior urethral valves who have undergone endoscopic injection to correct persistent reflux after successful relief of urethral obstruction. Breakthrough urinary tract infections, persistent highgrade reflux and failed ureteroneocystostomy were the indications of endoscopic antireflux surgery. Results: Reflux was grade I in 1, grade II in 3, grade III in 11 and grade IV in 4 ureters. Mean age at injection was 6.9 ± 3.8 years and the mean interval from initial intervention to injection was 4.3 ± 2.4 years. Injected material was dextranomer/hyaluronic acid in the majority (87.5 %) of cases. Reflux was resolved or downgraded in 12 ureters (63.1 %) after a single injection. All failed cases had urodynamically documented bladder dysfunction. Conclusion: More than half of the patients with vesicoureteral reflux, persisting after initial valve ablation, showed complete resolution or significant downgrading in their reflux grade after endoscopic injection. Given the technical difficulties and potential complications of open surgical reimplantation in valve patients, endoscopic subureteral injection can be considered as an effective alternative to cure persistent vesicoureteral reflux.

KW - Endoscopic injection

KW - Posterior urethral valve

KW - Vesicoureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=84867879634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867879634&partnerID=8YFLogxK

U2 - 10.1007/s11255-012-0240-y

DO - 10.1007/s11255-012-0240-y

M3 - Article

C2 - 22767179

AN - SCOPUS:84867879634

VL - 44

SP - 1305

EP - 1309

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 5

ER -